ZYME Zymeworks Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$25,15
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$16,0052-Wochen-Tief
$31,3452-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.80B
P/E (TTM)
-12.5
EPS (TTM)
$-2.02
Umsatz (TTM)
$37M
Ihre Abzeichen
52W-Spanne
$16–$31
Analystenbewertung
BUY
Kursziel
$41
P/E
-12.5
ROE
-72.3%
Nettogewinnmarge
-404.0%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
ZYME Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$25.15
Marktkapitalisierung (MRQ)
$1.80B
P/E (TTM)
-12.5
EPS (TTM)
$-2.02
Umsatz (TTM)
$37M
ROE (TTM)
-72.3%
52W-Spanne
$16–$31
ZYME Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Zymeworks Inc. - Common Stock Unternehmensübersicht von Wikipedia
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.
In September 2019, Zymeworks announced that, following their clinical trials, it has been confirmed that their ZW25 monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments.
In May 2022, Zymeworks rejected an unsolicited takeover proposal from a Dubai hedge fund, All Blue Falcons FZE, an arm of All Blue Capital.
Azymetric
This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1. This scaffold can also be engineered with tailored effector function and optimized serum half-life.
Awards and recognition
Deal of the Year, Lifesciences BC Awards, 2018
Life Sciences Company of the Year, Lifesciences BC Awards, 2016
Emerging company of the year – Health, BIOTECanada Gold Leaf Awards, 2015
12th Place, BC's Leading Innovators, 2011
Life Science Emerging Rocket, 2009, 2010, 2011
Early stage Company of the year – Industrial & Agriculture, BIOTECanada Gold Leaf Awards, 2009
== References ==
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter231
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$106M2020-12-31 → 2025-12-31
EPS$-1.082020-12-31 → 2025-12-31
Freier Cashflow$-35M2023-12-31 → 2025-12-31
Nettogewinnmarge-404.0%2023-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ZYME | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -12.55-Jahres-Durchschnitt ≈-8.8 | ≈-8.8 | · | · | |
| P/S (TTM) | 48.45-Jahres-Durchschnitt ≈13.8 | ≈13.8 | 10.3 | Überbewertet | |
| K/B (MRQ) | 22.35-Jahres-Durchschnitt ≈4.0 | ≈4.0 | 3.7 | Überbewertet | |
| Kurs / FCF (TTM) | -14.95-Jahres-Durchschnitt ≈-24.0 | ≈-24.0 | · | · | |
| Kurs / Cashflow (TTM) | -15.05-Jahres-Durchschnitt ≈-25.0 | ≈-25.0 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 22.65-Jahres-Durchschnitt ≈3.4 | ≈3.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ZYME | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -419.0%5-Jahres-Durchschnitt ≈-149.5% | ≈-149.5% | -588.2% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -87.3%5-Jahres-Durchschnitt ≈-149.5% | ≈-149.5% | -588.2% | Schwach | |
| Vorgewinnmarge (TTM) | -407.8%5-Jahres-Durchschnitt ≈-128.3% | ≈-128.3% | -709.2% | Schwach | |
| Nettogewinnmarge (TTM) | -404.0%5-Jahres-Durchschnitt ≈-131.2% | ≈-131.2% | -507.2% | Schwach | |
| ROA (TTM) | -37.2%5-Jahres-Durchschnitt ≈-21.0% | ≈-21.0% | -29.6% | Spitzenklasse | |
| ROE (TTM) | -72.3%5-Jahres-Durchschnitt ≈-29.5% | ≈-29.5% | -42.0% | Spitzenklasse | |
| ROIC | -35.1%5-Jahres-Durchschnitt ≈-35.7% | ≈-35.7% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ZYME | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 6.35-Jahres-Durchschnitt ≈5.6 | ≈5.6 | 9.0 | Geringe Liquidität | |
| Quick Ratio | 1.15-Jahres-Durchschnitt ≈3.2 | ≈3.2 | 5.8 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | ZYME | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 38.9%5-Jahres-Durchschnitt ≈274.4% | ≈274.4% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -36.4%5-Jahres-Durchschnitt ≈10.2% | ≈10.2% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 22.2% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ZYME | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.35-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.2 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 3.55-Jahres-Durchschnitt ≈2.8 | ≈2.8 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$458.7K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-16.9%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 5, 2026 | $-0.62 | $-0.50 | -25.1% |
| 31. März 2026 | Mai 6, 2026 | $-0.59 | $-0.20 | -201.3% |
| 31. Dezember 2025 | $-0.55 | $-0.42 | -29.5% | |
| 30. September 2025 | $-0.26 | $-0.33 | 20.6% | |
| 30. Juni 2025 | $0.03 | $-0.50 | 106.0% | |
| 31. März 2025 | $-0.30 | $-0.42 | 28.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $106M | $76M | $76M | $412M | $27M | |
| R&D Expense | · | · | $144M | $209M | $200M | |
| SG&A Expense | $62M | $62M | $70M | $73M | $43M | |
| Operating Expenses | $199M | $213M | $214M | $282M | $242M | |
| Operating Income | $-93M | $-137M | $-138M | $131M | $-216M | |
| Other Non-op | $51.0K | $-218.0K | $291.0K | $-42.0K | $118.0K | |
| Pretax Income | $-80M | $-117M | $-119M | $135M | $-212M | |
| Income Tax | $1M | $6M | $-568.0K | $11M | $-516.0K | |
| Net Income | $-81M | $-123M | $-119M | $124M | $-212M | |
| EPS (Basic) | $-1.08 | $-1.62 | $-1.72 | $1.91 | $-4.11 | |
| EPS (Diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 | |
| Shares (Basic) | 75,404,897 | 75,846,681 | 68,863,010 | 65,194,775 | 51,553,869 | |
| Shares (Diluted) | 75,413,396 | 75,878,738 | 68,863,010 | 65,249,184 | 52,131,596 | |
| EBITDA | $-93M | $-137M | $-138M | · | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $66M | $158M | $401M | $202M | |
| Short-term Investments | · | · | $217M | $91M | $51M | |
| Receivables | $5M | $56M | $19M | $33M | $16M | |
| Prepaid Expense | $15M | $19M | $19M | $19M | $20M | |
| Current Assets | $249M | $300M | $413M | $545M | $288M | |
| PP&E (Net) | $16M | $18M | $20M | $25M | $23M | |
| PP&E (Gross) | $36M | $35M | $41M | $38M | $37M | |
| Accum. Depreciation | $21M | $18M | $21M | $13M | $14M | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | |
| Intangibles | $1M | $5M | $8M | $9M | $4M | |
| Total Assets | $347M | $463M | $581M | $649M | $389M | |
| Accounts Payable | $36M | $60M | $46M | $87M | $63M | |
| Current Liabilities | $42M | $88M | $56M | $96M | $72M | |
| Capital Leases | $15M | $16M | $22M | $25M | $31M | |
| Deferred Tax | $6M | $5M | $3M | $2M | $2M | |
| Other Non-current Liabilities | $278.0K | $923.0K | $2M | $3M | $3M | |
| Total Liabilities | $78M | $124M | $116M | $156M | $140M | |
| Common Stock | $1.11B | $1.02B | $997M | $886M | $741M | |
| Retained Earnings | $-953M | $-830M | $-677M | $-559M | $-683M | |
| AOCI | $-6M | $-7M | $-7M | $-7M | $-7M | |
| Stockholders' Equity | $269M | $339M | $465M | $493M | $249M | |
| Liabilities + Equity | $347M | $463M | $581M | $649M | $389M | |
| Shares Outstanding | 74,638,413 | 68,964,319 | 70,115,997 | 63,059,501 | 46,633,935 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $28M | $18M | $8M | $4M | $11M | |
| Deferred Tax | $945.0K | $691.0K | $-757.0K | $2M | $-953.0K | |
| Amort. of Intangibles | $4M | $4M | $3M | $1M | $3M | |
| Restructuring | · | · | $0 | · | · | |
| Operating Cash Flow | $-33M | $-110M | $-118M | $144M | $-192M | |
| CapEx | $2M | $2M | $2M | $8M | $12M | |
| Investing Cash Flow | $27M | $39M | $-207M | $-54M | $145M | |
| Stock Issued | $0 | $0 | $26M | $108M | $0 | |
| Stock Repurchased | $42M | $30M | $0 | $0 | · | |
| Net Stock Activity | $-42M | $-30M | $26M | · | · | |
| Financing Cash Flow | $-19M | $-20M | $82M | $109M | $8M | |
| Net Change in Cash | $-25M | $-91M | $-243M | $199M | $-40M | |
| Taxes Paid | $1M | $3M | $165.0K | $10M | · | |
| Free Cash Flow | $-35M | $-112M | $-121M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Margin | -87.3% | -179.7% | -181.6% | · | · | |
| Net Margin | -76.6% | -160.8% | -156.1% | · | · | |
| Pretax Margin | -75.3% | -152.8% | -156.9% | · | · | |
| EBITDA Margin | -87.3% | -179.7% | -181.6% | · | · | |
| ROA | -20.0% | -23.5% | -19.3% | · | · | |
| ROE | -26.9% | -34.8% | -26.7% | · | · | |
| ROIC | -35.1% | -42.6% | -29.6% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | 3.4 | 7.4 | · | · | |
| Quick Ratio | 1.1 | 1.4 | 7.1 | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 3.5 | 2.0 | 2.9 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Book Value / Share | $3.60 | $4.91 | $6.63 | · | · | |
| Revenue / Share | $1.41 | $1.01 | $1.10 | · | · | |
| Cash Flow / Share | $-0.44 | $-1.45 | $-1.72 | · | · | |
| Cash / Share | $0.55 | $0.96 | $2.25 | · | · | |
| EPS (TTM) | $-1.08 | $-1.62 | $-1.72 | $1.90 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue YoY | 38.9% | 0.38% | -81.6% | 1446.0% | -31.5% | |
| Revenue CAGR 3Y | -36.4% | 41.9% | 25.0% | · | · | |
| Revenue CAGR 5Y | 22.2% | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $106M | $76M | $76M | $412M | · | |
| Net Income TTM | $-81M | $-123M | $-119M | $124M | · | |
| Market Cap | $1.97B | $1.01B | $729M | · | · | |
| P/E | -24.4 | -9.0 | -6.0 | 4.1 | · | |
| P/S | 18.5 | 13.2 | 9.6 | · | · | |
| P/B | 7.3 | 3.0 | 1.6 | · | · | |
| P / Tangible Book | 7.7 | 3.1 | 1.6 | 1.0 | · | |
| P / Cash Flow | -59.5 | -9.2 | -6.2 | · | · | |
| P / FCF | -56.9 | -9.0 | -6.0 | · | · | |
| Earnings Yield | -4.1% | -11.1% | -16.6% | 24.2% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $2M | $3M | $28M | $49M | $27M | $31M | $16M | $19M | $10M | $17M | $17M | $7M | $36M | $402M | $3M | |
| R&D Expense | · | · | · | · | · | · | · | · | · | $32M | · | $33M | $39M | $46M | · | $37M | |
| SG&A Expense | $19M | $15M | $15M | $14M | $15M | $17M | $16M | $14M | $16M | $16M | $15M | $17M | $22M | $17M | $30M | $16M | |
| Operating Expenses | $47M | $50M | $47M | $50M | $49M | $53M | $53M | $50M | $62M | $48M | $40M | $50M | $61M | $63M | $83M | $53M | |
| Operating Income | $-42M | $-47M | $-44M | $-22M | $-674.0K | $-26M | $-22M | $-34M | $-43M | $-38M | $-23M | $-33M | $-54M | $-27M | $319M | $-50M | |
| Other Non-op | $196.0K | $120.0K | $-18.0K | $26.0K | $-621.0K | $49.0K | $-253.0K | $-37.0K | $53.0K | $19.0K | $-278.0K | $370.0K | $230.0K | $-31.0K | $-27.0K | $-98.0K | |
| Pretax Income | $-45M | $-46M | $-41M | $-18M | $2M | $-22M | $-18M | $-30M | $-38M | $-32M | $-19M | $-28M | $-49M | $-23M | $320M | $-48M | |
| Income Tax | $-273.0K | $-2M | $-270.0K | $1M | $-186.0K | $496.0K | $6M | $226.0K | $68.0K | $75.0K | $-5M | $1M | $2M | $1M | $11M | $-29.0K | |
| Net Income | $-45M | $-44M | $-41M | $-20M | $2M | $-23M | $-24M | $-30M | $-38M | $-32M | $-14M | $-29M | $-51M | $-24M | $309M | $-48M | |
| EPS (Basic) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.19 | $-0.41 | $-0.76 | $-0.36 | $4.78 | $-0.72 | |
| EPS (Diluted) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.18 | $-0.41 | $-0.76 | $-0.37 | $4.78 | $-0.72 | |
| Shares (Basic) | 72,993,313 | 74,668,790 | · | 75,767,778 | 75,337,168 | 75,171,020 | · | 76,128,531 | 76,392,593 | 76,214,833 | · | 70,575,773 | 67,281,028 | 66,739,308 | · | 66,477,016 | |
| Shares (Diluted) | 72,993,313 | 74,694,762 | · | 75,775,214 | 77,378,449 | 75,226,387 | · | 76,157,101 | 76,396,217 | 76,248,158 | · | 70,575,773 | 67,284,511 | 66,742,030 | · | 66,478,157 | |
| EBITDA | $-42M | $-47M | · | $-22M | $-674.0K | $-26M | · | $-34M | $-43M | $-38M | · | $-33M | $-54M | $-27M | · | $-50M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $179M | $244M | $41M | $65M | $98M | $76M | $66M | $122M | $71M | $115M | · | $94M | $142M | $182M | · | $96M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $201M | $198M | $159M | · | $70M | |
| Receivables | $6M | $5M | $5M | $29M | $3M | $25M | $56M | $24M | $32M | $31M | · | $67M | $49M | $67M | · | $7M | |
| Prepaid Expense | $22M | $16M | $15M | $10M | $12M | $17M | $19M | $23M | $21M | $18M | · | $12M | $31M | $19M | · | $18M | |
| Current Assets | $298M | $386M | $249M | $292M | $296M | $306M | $300M | $344M | $383M | $394M | · | $375M | $420M | $426M | · | $191M | |
| PP&E (Net) | $14M | $15M | $16M | $16M | $16M | $17M | $18M | $18M | $18M | $19M | · | $21M | $22M | $24M | · | $26M | |
| PP&E (Gross) | · | · | $36M | · | · | · | $35M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $21M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Intangibles | $998.0K | $1M | $1M | $1M | $2M | $3M | $5M | $6M | $7M | $7M | · | $8M | $7M | $8M | · | $9M | |
| Total Assets | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Accounts Payable | $27M | $30M | $36M | $34M | $31M | $38M | $60M | $52M | $44M | $47M | · | $68M | $70M | $59M | · | $52M | |
| Current Liabilities | $47M | $36M | $42M | $42M | $39M | $65M | $88M | $84M | $55M | $57M | · | $73M | $94M | $67M | · | $58M | |
| Capital Leases | $13M | $14M | $15M | $16M | $15M | $15M | $16M | $17M | $17M | $21M | · | $22M | $23M | $24M | · | $25M | |
| Deferred Tax | $4M | $4M | $6M | $5M | $5M | $5M | $5M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Other Non-current Liabilities | $278.0K | $278.0K | $278.0K | $278.0K | $828.0K | $856.0K | $923.0K | $929.0K | $1M | $2M | · | $2M | $4M | $4M | · | $3M | |
| Total Liabilities | $317M | $315M | $78M | $77M | $74M | $101M | $124M | $120M | $109M | $116M | · | $132M | $153M | $127M | · | $121M | |
| Common Stock | $1.13B | $1.13B | $1.11B | $1.09B | $1.07B | $1.02B | $1.02B | $1.01B | $1.01B | $1.00B | · | $932M | $929M | $900M | · | $885M | |
| Retained Earnings | $-1.17B | $-1.07B | $-953M | $-886M | $-851M | $-853M | $-830M | $-798M | $-747M | $-709M | · | $-663M | $-634M | $-583M | · | $-868M | |
| AOCI | $-7M | $-7M | $-6M | $-6M | $-6M | $-6M | $-7M | $-6M | $-8M | $-8M | · | $-8M | $-8M | $-6M | · | $-7M | |
| Stockholders' Equity | $80M | $164M | $269M | $320M | $335M | $325M | $339M | $367M | $406M | $438M | $465M | $424M | $449M | $474M | $493M | $180M | |
| Liabilities + Equity | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Shares Outstanding | 71,412,072 | 73,102,689 | 74,638,413 | 75,139,281 | 74,846,147 | 69,584,811 | 68,964,319 | 69,584,882 | 70,831,545 | 70,677,106 | · | 67,922,559 | 67,687,384 | 64,083,770 | · | 61,694,387 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $11M | $7M | $9M | $7M | $6M | $6M | $5M | $5M | $5M | $4M | $3M | $2M | $367.0K | $2M | $4M | $5M | |
| Amort. of Intangibles | $176.0K | $176.0K | $185.0K | $648.0K | $2M | $2M | $2M | $980.0K | $812.0K | $702.0K | $673.0K | $672.0K | $678.0K | $679.0K | $529.0K | $166.0K | |
| Operating Cash Flow | $-32M | $-46M | $-10M | $-31M | $12M | $-3M | $-42M | $-6M | $-25M | $-38M | $14M | $-43M | $-6M | $-83M | $327M | $-73M | |
| CapEx | $0 | $216.0K | $581.0K | $410.0K | $514.0K | $16.0K | $314.0K | $899.0K | $593.0K | $185.0K | $356.0K | $930.0K | $802.0K | $386.0K | $348.0K | $981.0K | |
| Investing Cash Flow | $17M | $70M | $5M | $368.0K | $9M | $12M | $-6M | $72M | $-20M | $-7M | $-1M | $-7M | $-61M | $-138M | $-22M | $-30M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | · | $0 | $0 | $26M | $0 | $0 | $0 | |
| Stock Repurchased | $52M | $76M | $25M | $16M | $0 | $0 | $9M | · | · | · | $0 | · | · | · | · | · | |
| Net Stock Activity | · | $-76M | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-50M | $179M | $-19M | $-2M | $1M | $1M | $-9M | $-15M | $1M | $2M | $51M | $2M | $28M | $2M | $-377.0K | $628.0K | |
| Net Change in Cash | $-65M | $203M | $-24M | $-33M | $22M | $10M | $-56M | $51M | $-44M | $-43M | $63M | $-48M | $-39M | $-219M | $305M | $-103M | |
| Taxes Paid | $863.0K | $245.0K | $107.0K | $660.0K | $196.0K | $387.0K | $3M | $106.0K | $106.0K | $0 | · | · | · | · | · | · | |
| Free Cash Flow | · | $-46M | · | · | · | $-3M | · | · | · | $-38M | · | · | · | $-84M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| Net Margin | -980.8% | -1834.0% | · | -71.0% | 4.8% | -83.5% | · | -186.6% | -195.8% | -315.6% | · | -173.8% | -730.5% | -68.5% | · | -1818.6% | |
| Pretax Margin | -986.8% | -1925.0% | · | -66.1% | 4.4% | -81.7% | · | -185.2% | -195.5% | -314.8% | · | -167.1% | -706.9% | -64.5% | · | -1819.7% | |
| EBITDA Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| ROA | -11.2% | -9.8% | · | -4.4% | 0.50% | -4.6% | · | -5.7% | -6.7% | -5.5% | · | -6.7% | -17.0% | -8.1% | · | -31.9% | |
| ROE | -21.7% | -18.1% | · | -5.7% | 0.63% | -5.9% | · | -7.5% | -8.8% | -6.9% | · | -9.5% | -22.8% | -10.3% | · | -53.2% | |
| ROIC | -52.2% | -27.4% | · | -7.4% | -0.22% | -8.1% | · | -9.4% | -10.6% | -8.6% | · | -8.2% | -12.5% | -6.1% | · | -28.0% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 10.8 | · | 6.9 | 7.7 | 4.7 | · | 4.1 | 7.0 | 6.9 | · | 5.1 | 4.5 | 6.3 | · | 3.3 | |
| Quick Ratio | 3.9 | 7.0 | · | 2.2 | 2.6 | 1.5 | · | 1.7 | 1.9 | 2.6 | · | 5.0 | 4.2 | 6.1 | · | 3.0 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | |
| Receivables Turnover | 1.1 | 0.2 | · | 1.0 | 2.8 | 1.0 | · | 0.4 | 0.5 | 0.2 | · | 0.4 | 0.3 | 1.1 | · | 0.8 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.13 | $2.24 | · | $4.26 | $4.47 | $4.67 | · | $5.27 | $5.73 | $6.20 | · | $6.25 | $6.63 | $7.39 | · | $2.91 | |
| Revenue / Share | $0.06 | $0.03 | · | $0.36 | $0.63 | $0.36 | · | $0.21 | $0.25 | $0.13 | · | $0.23 | $0.10 | $0.53 | · | $0.04 | |
| Cash Flow / Share | · | $-0.61 | · | · | · | $-0.05 | · | · | · | $-0.49 | · | · | · | $-1.25 | · | · | |
| Cash / Share | $2.51 | $3.34 | · | $0.86 | $1.31 | $1.10 | · | $1.76 | $1.00 | $1.62 | · | $1.39 | $2.10 | $2.83 | · | $1.56 | |
| EPS (TTM) | $-2.02 | $-1.37 | · | $-0.85 | $-0.98 | $-1.50 | · | $-1.48 | $-1.50 | $-1.77 | · | $3.24 | $2.93 | $2.72 | · | $-3.83 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $81M | · | $134M | $123M | $93M | · | $62M | $63M | $50M | · | $462M | $448M | $446M | · | $30M | |
| Net Income TTM | $-150M | $-103M | · | $-63M | $-74M | $-114M | · | $-114M | $-113M | $-126M | · | $205M | $186M | $173M | · | $-224M | |
| Market Cap | $1.87B | $1.83B | · | $1.28B | $939M | $829M | · | $873M | $603M | $744M | · | $431M | $585M | $579M | · | $379M | |
| P/E | -12.9 | -18.3 | · | -20.1 | -12.8 | -7.9 | · | -8.5 | -5.7 | -5.9 | · | 2.0 | 2.9 | 3.3 | · | -1.6 | |
| P/S | 50.3 | 22.5 | · | 9.5 | 7.6 | 8.9 | · | 14.0 | 9.6 | 14.7 | · | 0.9 | 1.3 | 1.3 | · | 12.7 | |
| P/B | 23.2 | 11.2 | · | 4.0 | 2.8 | 2.6 | · | 2.4 | 1.5 | 1.7 | · | 1.0 | 1.3 | 1.2 | · | 2.1 | |
| P / Tangible Book | 27.7 | 12.2 | · | 4.2 | 2.9 | 2.7 | · | 2.5 | 1.6 | 1.8 | · | 1.1 | 1.4 | 1.3 | · | 2.4 | |
| P / Cash Flow | · | -40.0 | · | · | · | -243.3 | · | · | · | -19.7 | · | · | · | -7.0 | · | · | |
| Earnings Yield | -7.7% | -5.5% | · | -5.0% | -7.8% | -12.6% | · | -11.8% | -17.6% | -16.8% | · | 51.1% | 33.9% | 30.1% | · | -62.3% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $106M | $76M | $76M | $412M | $27M |
| Betriebsgewinnmarge % | -87.3% | -179.7% | -181.6% | · | · |
| Nettoergebnis | $-81M | $-123M | $-119M | $124M | $-212M |
| Verwässerte EPS | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.9 | 3.4 | 7.4 | · | · |
| Quick Ratio | 1.1 | 1.4 | 7.1 | · | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-35M | $-112M | $-121M | · | · |
Institutionelle Eigentümer (13F) 212 Einreicher · $1.9B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
212
Gehaltener Wert
$1.9B
Neue Positionen
22
Geschlossene Positionen
31
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 22 (-20 vs. Vorquartal) | 31 (0 vs. Vorquartal) | 59 (-16 vs. Vorquartal) | 73 (+13 vs. Vorquartal) | -2.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| EcoR1 Capital, LLC | $600.445.942 | 22.970.388 | 32,29% | Aktien |
| Rubric Capital Management LP | $182.980.000 | 7.000.000 | 9,84% | Aktien |
| BlackRock, Inc. | $111.121.925 | 4.251.030 | 5,98% | Aktien |
| PERCEPTIVE ADVISORS LLC | $109.342.391 | 4.182.953 | 5,88% | Aktien |
| BVF INC/IL | $95.388.572 | 3.649.142 | 5,13% | Aktien |
| VANGUARD GROUP INC | $61.315.382 | 2.328.727 | 3,30% | Aktien |
| MORGAN STANLEY | $58.325.141 | 2.231.260 | 3,14% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $46.558.373 | 1.781.116 | 2,50% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.752.208 | 1.558.998 | 2,19% | Aktien |
| Assenagon Asset Management S.A. | $32.727.986 | 1.252.027 | 1,76% | Aktien |
| Nextech Invest Ltd. | $29.118.548 | 1.113.946 | 1,57% | Aktien |
| STATE STREET CORP | $28.445.966 | 1.088.216 | 1,53% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $25.995.770 | 994.955 | 1,40% | Aktien |
| CITADEL ADVISORS LLC | $23.895.516 | 914.136 | 1,29% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $23.259.000 | 889.802 | 1,25% | Aktien |
| FMR LLC | $18.365.133 | 702.568 | 0,99% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $18.099.012 | 692.410 | 0,97% | Aktien |
| Prosight Management, LP | $17.629.705 | 674.434 | 0,95% | Aktien |
| Qube Research & Technologies Ltd | $15.516.443 | 593.590 | 0,83% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.332.236 | 510.032 | 0,72% | Aktien |
| Redmile Group, LLC | $12.851.836 | 491.654 | 0,69% | Aktien |
| Capricorn Fund Managers Ltd | $12.717.868 | 486.529 | 0,68% | Aktien |
| GOLDMAN SACHS GROUP INC | $12.307.288 | 470.822 | 0,66% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $10.939.512 | 418.497 | 0,59% | Aktien |
| DEUTSCHE BANK AG\ | $10.382.547 | 397.190 | 0,56% | Aktien |
| Hillsdale Investment Management Inc. | $10.009.581 | 382.922 | 0,54% | Aktien |
| FIRST TRUST ADVISORS LP | $8.897.088 | 340.363 | 0,48% | Aktien |
| Granahan Investment Management, LLC | $8.787.144 | 336.157 | 0,47% | Aktien |
| NORTHERN TRUST CORP | $8.392.849 | 321.073 | 0,45% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $7.997.401 | 319.385 | 0,43% | Aktien |
| Pictet Asset Management Holding SA | $7.446.189 | 308.187 | 0,40% | Aktien |
| PICTON MAHONEY ASSET MANAGEMENT | $7.092.908 | 271.343 | 0,38% | Aktien |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.849.243 | 223.766 | 0,31% | Aktien |
| BANK OF AMERICA CORP /DE/ | $5.726.515 | 219.071 | 0,31% | Aktien |
| WELLS FARGO & COMPANY/MN | $5.677.573 | 217.199 | 0,31% | Aktien |
| SummitTX Capital, L.P. | $5.510.364 | 210.802 | 0,30% | Aktien |
| Man Group plc | $5.509.763 | 210.779 | 0,30% | Aktien |
| FEDERATED HERMES, INC. | $4.914.190 | 187.995 | 0,26% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $4.350.114 | 166.416 | 0,23% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.066.835 | 155.579 | 0,22% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.984.154 | 152.416 | 0,21% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.800.390 | 145.386 | 0,20% | Aktien |
| D. E. Shaw & Co., Inc. | $3.785.255 | 144.807 | 0,20% | Aktien |
| DIADEMA PARTNERS LP | $3.715.330 | 142.132 | 0,20% | Aktien |
| CITIGROUP INC | $3.435.868 | 131.441 | 0,18% | Aktien |
| Bank of New York Mellon Corp | $3.427.107 | 131.106 | 0,18% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.408.656 | 130.400 | 0,18% | Kaufoption |
| XTX Topco Ltd | $3.290.425 | 125.877 | 0,18% | Aktien |
| Nuveen, LLC | $3.120.829 | 119.389 | 0,17% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $3.100.282 | 118.603 | 0,17% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. ×8 Einreichungen | 19. November 2025 | 30,70% | Änderung | Vorstandskampagne | SEC |
| All Blue Falcons FZE, Daniel Edward Llewellen Cookson ×2 Einreichungen | 28. Dezember 2022 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 28 Insider · 12 Führungskräfte · 17 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO | 12. Januar 2026 A | 226.842 | 0 | 4 | $-3.337.929 |
| Kristin Stafford | EVP, Chief Financial Officer | 6. April 2026 A | · | 0 | 0 | $0 |
| Christopher Astle | SVP & Chief Financial Officer | 5. Januar 2024 A | 6.503 | 0 | 0 | $0 |
| Neil A Klompas | President & COO | 10. März 2023 M | 17.032 | 0 | 0 | $0 |
| Mark Hollywood | EVP & Chief Operating Officer | 6. Juli 2026 A | 133.852 | 0 | 1 | $-138.740 |
| Paul R Schneider | EVP, General Counsel | 13. Mai 2026 A | · | 0 | 0 | $0 |
| Adam Schayowitz | EVP, Head of Research & Development | 9. April 2026 A | · | 0 | 0 | $0 |
| Scott Platshon | EVP, Chief Business Officer | 9. April 2026 A | · | 0 | 0 | $0 |
| Paul Andrew Moore | Chief Scientific Officer | 12. Januar 2026 A | 48.497 | 0 | 3 | $-721.486 |
| Jeffrey T L Smith | EVP & Chief Medical Officer | 12. Januar 2026 M | 26.708 | 0 | 2 | $-475.562 |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | 6. Januar 2026 A | 459 | 0 | 0 | $0 |
| Neil Josephson | Chief Medical Officer | 10. November 2022 M | 14.449 | 0 | 0 | $0 |
| Gregory A. Ciongoli | Direktor | 12. Januar 2026 A | 488.500 | 0 | 0 | $0 |
| Alessandra Cesano | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Carlos Campoy | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Robert E Landry | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Kelvin Neu | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Susan Mahony | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Brian N Cherry | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| EcoR1 Capital, LLC | Direktor | 17. Januar 2025 P | 15.720.161 | 0 | 0 | $0 |
| Nancy Davidson | Direktor | 10. Dezember 2024 A | · | 0 | 0 | $0 |
| Neil Gallagher | Direktor | 10. Dezember 2024 A | · | 0 | 0 | $0 |
| Derek John Michael Miller | Direktor | 10. Dezember 2024 A | · | 0 | 0 | $0 |
| Troy Cox | Direktor | 10. Dezember 2024 A | · | 0 | 0 | $0 |
| Kenneth J. Hillan | Direktor | 7. Dezember 2023 A | · | 0 | 0 | $0 |
| Hollings Renton | Direktor | 7. Dezember 2023 A | · | 0 | 0 | $0 |
| Natalie Sacks | Direktor | 21. Dezember 2022 A | · | 0 | 0 | $0 |
| Lota S. Zoth | Direktor | 21. Dezember 2022 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 30 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,32% | 59.315 NS | 31. Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,15% | 14.705 SH | 1. Oktober 2026 | Täglich |
| IBB · iShares Trust | 0,14% | 537.742 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,12% | 5.008 SH | 1. Oktober 2026 | Täglich |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,11% | 65.877 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,10% | 74.514 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,08% | 439.290 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 50.443 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 68.050 SH | 1. Oktober 2026 | Täglich |
| IWM · iShares Trust | 0,04% | 1.202.863 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 270.692 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,03% | 22.528 NS | 31. Juli 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,03% | 189.632 NS | 31. Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,02% | 5.969 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,02% | 5.910 SH | 11. September 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 18.267 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 3.039 SH | 11. September 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 110.298 SH | 19. August 2026 | Täglich |
| TILT · FlexShares Trust | 0,01% | 5.508 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 70.572 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 3.968 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 12.951 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 14.406 SH | 10. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 8.364 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 130 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.508.613 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.085 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 1.999 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 5.753 SH | 11. September 2026 | Täglich |
| SMMV · iShares Trust | · | 16.029 SH | 19. August 2026 | Täglich |
ZYME Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 18 Analysten
KAUF
Median-Ziel
$38.00
+51,1%
6 33,3%
Starker Kauf
11 61,1%
Kauf
1 5,6%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
13 Analysten · 2026-09-27Mittelwert-Ziel $41.23 +63,9%
← Unter allen Zielen
Aktueller Preis $25.15
Tief$32.00
Mittelwert$41.23
Hoch$60.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026